NCT06504732View on ClinicalTrials.gov

To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

August 15, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2028

Conditions
Stomach NeoplasmsSolid Tumor
Interventions
DRUG

IAH0968

Subjects were treated with IAH0968 in combination with or without the CAPEOX regimen in the corresponding groups. Every 3 weeks was defined as a treatment cycle and IAH0968 was used for a maximum of 35 cycles.

Trial Locations (2)

637000

RECRUITING

The First Hospital of China Medical University, Shenyang

Unknown

RECRUITING

The First Hospital of China Medical University, Shenyang

All Listed Sponsors
lead

SUNHO（China）BioPharmaceutical CO., Ltd.

INDUSTRY